CLOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

Squaremouth Inc

Squaremouth.com, and their multi-award winning customer service team, has helped over 2.5 million travelers save time and money to find the best travel insurance policy for their trip. Leveraging decades of travel expertise, and industry-leading technology, Squaremouth.com hosts the most intuitive travel insurance quoting and comparison engine on the market today. Coupled with verified customer reviews and the largest portfolio of products, Squaremouth allows travelers to instantly purchase a travel insurance policy from every major provider in the US.

The IRONMAN Group

The IRONMAN Group is a leading organization in endurance sports, hosting over 230 events annually in more than 55 countries. Founded in 1978 with the first Hawaiian Iron Man Triathlon, the company has evolved from a single race into a global phenomenon, attracting over 600,000 participants each year. It operates as the largest mass-participation sports organizer worldwide, originally established as the World Triathlon Corporation in 1991. The IRONMAN Group offers a diverse portfolio of events, including the full-distance IRONMAN® Triathlon, the half-distance IRONMAN® 70.3®, and the Olympic-distance 5150™ Triathlon Series. They also organize running events like the Rock ‘n’ Roll® Running Series and the Standard Chartered Singapore Marathon™, as well as trail running and cycling events. The company promotes inclusivity, catering to elite athletes, amateur enthusiasts, families, and youth through programs like IRONKIDS® and Iron Girl®. Their mission is to inspire athletes of all levels with the ethos "ANYTHING IS POSSIBLE®."

Meyer Lab

Meyer Laboratory, also known as Meyer Lab, is a U.S.-based chemical manufacturer that specializes in industrial and institutional cleaning chemicals and application systems. Founded in 1978 by Russ Meyer, the company has established itself as a leader in the North American market for industrial cleaning solutions. Meyer Lab focuses on delivering customized cleaning programs that meet the specific needs of its customers. The company offers a wide range of services, including tailored cleaning programs that aim to reduce chemical and labor costs, maintenance services for cleaning equipment, and training for effective product use. Meyer Lab also provides inventory management assistance and supplies advanced dispensing systems to enhance safety and efficiency in chemical use. Their product portfolio features various hard surface cleaning chemicals, such as degreasers, disinfectants, sanitizers, and surfactant blends, which are designed for multiple industrial and manufacturing markets. Meyer Lab is committed to supporting environmental initiatives by providing effective and efficient cleaning solutions.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.